Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130 on ClinicalTrials.gov · last registry update 2025-03-20

Finished 16 October 2024, after enrolling 69 people. Primary outcome, as filed: Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Colorado, Denver
Sponsor type: Other
Enrollment: 69
Started: 2022-01-01
Primary completion: 2024-10-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups

Conditions studied

Type 2 Diabetes · Chronic Inflammation · Intestinal Permeability

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.